Jordan, Karin
Chan, Alexandre
Gralla, Richard J.
Jahn, Franziska
Rapoport, Bernardo
Ruhlmann, Christina H.
Sayegh, Paula
Hesketh, Paul J.
Funding for this research was provided by:
Medizinische Fakultät Heidelberg der Universität Heidelberg
Article History
Accepted: 1 December 2023
First Online: 22 December 2023
Declarations
:
: The authors have the following conflicts of interest to disclose:Karin Jordan: reports personal fees as an invited speaker from Amgen, art tempi, Helsinn, Hexal, med update GmbH, MSD, Mundipharma, onkowissen, Riemser, Roche, Shire (Takeda), and Vifor; personal fees for advisory board membership from Amgen, AstraZeneca, BD Solutions, Hexal, Karyopharm, and Voluntis; personal fees as author for UpToDate.Alexandre Chan: received honorarium from Eli Lilly, Blueprint Medicine, and HengRui USA.Richard J. Gralla: received honoraria from Fosun, Helsinn Healthcare SA, Juniper Biologics, Knight Therapeutics, Mundipharma International Limited, Vifor Pharma.Franziska Jahn: received honorarium and a travel grant from Amgen.Bernardo Rapoport: reports personal fees as an invited speaker from MSD, personal fees, and a research grant from Tesaro (GSK now).Christina Ruhlmann: received honoraria (speaker) from Bristol Myers Squibb (BMS), Helsinn Healthcare SA, and Pharmanovia, and funding for a clinical trial from Helsinn Healthcare SA and the Novo Nordic Foundation.Paula Sayegh: nothing to disclose.Paul J. Hesketh: nothing to disclose.